A composition for use in the prevention and/or treatment of colorectal cancer in a patient, comprising: a) a compound of Formula or a salt, co-crystal or solvate thereof, where R 1, R 2, and R 3 are, each one and independently, hydrogen or a moiety selected from an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof, R 5, R 6, R 7, R 8, R 9 and R 10 are, each one and independently, hydrogen, hydroxyl or an -OR 4 group, where R 4 is a moiety selected from an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an aldehyde group, a sulfoxide group or a combination thereof, more preferably an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkenyl group, an alkynyl group, or a combination thereof; and b) at least one chemotherapeutic agent, or a salt, co-crystal or solvate thereof, wherein said chemotherapeutic agent is 5-fluorouracil; and wherein said composition comprises a molar ratio of the compound of Formula to the at least one chemotherapeutic agent from 1:10 to 1:36. a) a compound of Formula or a salt, co-crystal or solvate thereof, where R 1, R 2, and R 3 are, each one and independently, hydrogen or a moiety selected from an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof, R 5, R 6, R 7, R 8, R 9 and R 10 are, each one and independently, hydrogen, hydroxyl or an -OR 4 group, where R 4 is a moiety selected from an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an aldehyde group, a sulfoxide group or a combination thereof, more preferably an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkenyl group, an alkynyl group, or a combination thereof; and R 1, R 2, and R 3 are, each one and independently, hydrogen or a moiety selected from an alkyl group, a cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an alkylaryl group, an ester group, a carbonate group, a carboxylic acid group, an aldehyde group, a ketone group, a urethane group, a silyl group, a sulfoxide group or a combination thereof, R 5, R 6, R 7, R 8, R 9 and R 10 are, each one and independently, hydrogen, hydroxyl or an -OR 4 group, where R 4 is a moiety selected from an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic aryl group, an aldehyde group, a sulfoxide group or a combination thereof, more preferably an alkyl group, a cycloalkyl group, a halogenated alkyl group, an alkenyl group, an alkynyl group, or a combination thereof; and b) at least one chemotherapeutic agent, or a salt, co-crystal or solvate thereof, wherein said chemotherapeutic agent is 5-fluorouracil; and wherein said composition comprises a molar ratio of the compound of Formula to the at least one chemotherapeutic agent from 1:10 to 1:36.